Q3 2023 Earnings Forecast for Compugen Ltd. Issued By Oppenheimer (NASDAQ:CGEN)

Compugen Ltd. (NASDAQ:CGEN – Get Rating) – Investment analysts at Oppenheimer issued their Q3 2023 earnings estimates for Compugen in a report issued on Monday, May 16th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.14) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $14.00 price target on the stock.

Compugen (NASDAQ:CGEN – Get Rating) last announced its earnings results on Monday, May 16th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. During the same quarter last year, the company posted ($0.12) EPS.

Several other research analysts have also commented on the stock. SVB Leerink cut their price target on shares of Compugen from $16.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, February 25th. Zacks Investment Research cut Compugen from a “buy” rating to a “hold” rating in a research report on Wednesday, April 27th. Finally, StockNews.com cut shares of Compugen from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $11.13.

NASDAQ:CGEN opened at $2.03 on Wednesday. Compugen has a 12-month low of $1.66 and a 12-month high of $9.20. The company’s 50-day moving average is $2.73 and its two-hundred day moving average is $3.67.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. purchased a new position in shares of Compugen during the 2nd quarter valued at $92,000. Morgan Stanley lifted its stake in Compugen by 9.6% during the 2nd quarter. Morgan Stanley now owns 1,789,967 shares of the biotechnology company’s stock valued at $14,820,000 after acquiring an additional 157,025 shares during the period. Raymond James & Associates grew its position in shares of Compugen by 31.6% during the 3rd quarter. Raymond James & Associates now owns 202,495 shares of the biotechnology company’s stock valued at $1,209,000 after acquiring an additional 48,600 shares during the period. BlackRock Inc. grew its position in shares of Compugen by 6.7% during the third quarter. BlackRock Inc. now owns 2,538,702 shares of the biotechnology company’s stock worth $15,156,000 after purchasing an additional 160,523 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Compugen by 58.8% in the 3rd quarter. Barclays PLC now owns 13,562 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,024 shares in the last quarter.

Compugen Company Profile (Get Rating)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Further Reading